Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
Ann Transl Med
.
2020 Apr;8(8):555.
doi: 10.21037/atm.2020.01.87.
Authors
Madhawa de Silva
1
,
Malinda Itchins
1
,
Nick Pavlakis
1
Affiliation
1
Department of Medical Oncology, Royal North Shore Hospital, Sydney University, Sydney, Australia.
PMID:
32411778
PMCID:
PMC7214900
DOI:
10.21037/atm.2020.01.87
No abstract available
Publication types
Editorial
Comment